APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gene Therapy

Gene therapy is an experimental treatment that involves introducing genetic material into a person’s cells to fight or prevent disease. Researchers are studying gene therapy for a number of diseases, such as severe combined immuno-deficiencies, hemophilia, Parkinson's disease, cancer and even HIV, through a number of different approaches. A gene can be delivered to a cell using a carrier known as a “vector.” The most common types of vectors used in gene therapy are viruses. The viruses used in gene therapy are altered to make them safe, although some risks still exist with gene therapy. The technology is still in its infancy.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Gene therapy is an experimental treatment that involves introducing genetic material into a person’s cells to fight or prevent disease. Researchers are studying gene therapy for a number of diseases, such as severe combined immuno-deficiencies, hemophilia, Parkinson's disease, cancer and even HIV, through a number of different approaches. A gene can be delivered to a cell using a carrier known as a “vector.” The most common types of vectors used in gene therapy are viruses. The viruses used in gene therapy are altered to make them safe, although some risks still exist with gene therapy. The technology is still in its infancy.

Selected research

Market Outlook & Growth Opportunities

Global Gene Therapy Market Outlook and Growth Opportunities 2026

21 December 2025199 pages

Choose your research edition.

Industry ResearchGene Therapy Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Gene Therapy Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Gene Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gene Therapy Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Gene Therapy Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

Gene therapy is an experimental treatment that involves introducing genetic material into a person’s cells to fight or prevent disease. Researchers are studying gene therapy for a number of diseases, such as severe combined immuno-deficiencies, hemophilia, Parkinson's disease, cancer and even HIV, through a number of different approaches. A gene can be delivered to a cell using a carrier known as a “vector.” The most common types of vectors used in gene therapy are viruses. The viruses used in gene therapy are altered to make them safe, although some risks still exist with gene therapy. The technology is still in its infancy.

Global Gene Therapy key players include Biogen, Novartis, Gilead Sciences, etc. Global top three manufacturers hold a share about 75%.

North America is the largest market, with a share about 60%, followed by Europe and Asia-Pacific, both have a share about 35 percent.

Read the full market overview

In terms of product, Non-viral Gene Therapy is the largest segment, with a share about 55%. And in terms of application, the largest application is Neurological Diseases, followed by Cancer.

This report provides an overview of the global Gene Therapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gene Therapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gene Therapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Gene Therapy market.

Gene Therapy Segment by Company

Biogen

Novartis

Gilead Sciences

Sarepta Therapeutics

Alnylam Pharmaceuticals

Amgen

Spark Therapeutics

Akcea Therapeutics

bluebird bio

Sunway Biotech

SIBIONO

AnGes

Orchard Therapeutics

Human Stem Cells Institute

Gene Therapy Segment by Type

Viral Gene Therapy

Non-Viral Gene Therapy

Gene Therapy Segment by Application

Neurological Diseases

Cancer

Other

Gene Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Gene Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Gene Therapy key companies, revenue, market share, and recent developments.

3. To split the Gene Therapy breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Gene Therapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Gene Therapy significant trends, drivers, influence factors in global and regions.

6. To analyze Gene Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gene Therapy industry.

Chapter 3: Detailed analysis of Gene Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Gene Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Gene Therapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Gene Therapy Industry Trends Table 2. Gene Therapy Industry Drivers Table 3. Gene Therapy Industry Opportunities and Challenges Table 4. Gene Therapy Industry Restraints Table 5. Global Gene Therapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Gene Therapy Revenue Share by Company (2021-2026) Table 7. Global Gene Therapy Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Gene Therapy Key Company Manufacturing Base & Headquarters Table 9. Global Gene Therapy Company, Product Type & Application Table 10. Global Gene Therapy Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Gene Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Viral Gene Therapy Table 15. Significant Companies of Non-Viral Gene Therapy Table 16. Global Gene Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Gene Therapy Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Gene Therapy Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Gene Therapy Sales Value Share by Type (2021-2026) Table 20. Global Gene Therapy Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Neurological Diseases Table 22. Significant Companies of Cancer Table 23. Significant Companies of Other Table 24. Global Gene Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Gene Therapy Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Gene Therapy Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Gene Therapy Sales Value Share by Application (2021-2026) Table 28. Global Gene Therapy Sales Value Share by Application (2027-2032) Table 29. Global Gene Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Gene Therapy Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Gene Therapy Sales Value Share by Region (2021-2026) Table 32. Global Gene Therapy Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Gene Therapy Sales Value Share by Region (2027-2032) Table 34. Global Gene Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Gene Therapy Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Gene Therapy Sales Value Market Share by Country (2021-2026) Table 37. Global Gene Therapy Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Gene Therapy Sales Value Market Share by Country (2027-2032) Table 39. Biogen Company Information Table 40. Biogen Business Overview Table 41. Biogen Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Biogen Gene Therapy Product Portfolio Table 43. Biogen Recent Development Table 44. Novartis Company Information Table 45. Novartis Business Overview Table 46. Novartis Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Novartis Gene Therapy Product Portfolio Table 48. Novartis Recent Development Table 49. Gilead Sciences Company Information Table 50. Gilead Sciences Business Overview Table 51. Gilead Sciences Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Gilead Sciences Gene Therapy Product Portfolio Table 53. Gilead Sciences Recent Development Table 54. Sarepta Therapeutics Company Information Table 55. Sarepta Therapeutics Business Overview Table 56. Sarepta Therapeutics Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Sarepta Therapeutics Gene Therapy Product Portfolio Table 58. Sarepta Therapeutics Recent Development Table 59. Alnylam Pharmaceuticals Company Information Table 60. Alnylam Pharmaceuticals Business Overview Table 61. Alnylam Pharmaceuticals Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Alnylam Pharmaceuticals Gene Therapy Product Portfolio Table 63. Alnylam Pharmaceuticals Recent Development Table 64. Amgen Company Information Table 65. Amgen Business Overview Table 66. Amgen Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Amgen Gene Therapy Product Portfolio Table 68. Amgen Recent Development Table 69. Spark Therapeutics Company Information Table 70. Spark Therapeutics Business Overview Table 71. Spark Therapeutics Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Spark Therapeutics Gene Therapy Product Portfolio Table 73. Spark Therapeutics Recent Development Table 74. Akcea Therapeutics Company Information Table 75. Akcea Therapeutics Business Overview Table 76. Akcea Therapeutics Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Akcea Therapeutics Gene Therapy Product Portfolio Table 78. Akcea Therapeutics Recent Development Table 79. bluebird bio Company Information Table 80. bluebird bio Business Overview Table 81. bluebird bio Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. bluebird bio Gene Therapy Product Portfolio Table 83. bluebird bio Recent Development Table 84. Sunway Biotech Company Information Table 85. Sunway Biotech Business Overview Table 86. Sunway Biotech Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Sunway Biotech Gene Therapy Product Portfolio Table 88. Sunway Biotech Recent Development Table 89. SIBIONO Company Information Table 90. SIBIONO Business Overview Table 91. SIBIONO Gene Therapy Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 92. SIBIONO Gene Therapy Product Portfolio Table 93. SIBIONO Recent Development Table 94. AnGes Company Information Table 95. AnGes Business Overview Table 96. AnGes Gene Therapy Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 97. AnGes Gene Therapy Product Portfolio Table 98. AnGes Recent Development Table 99. Orchard Therapeutics Company Information Table 100. Orchard Therapeutics Business Overview Table 101. Orchard Therapeutics Gene Therapy Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 102. Orchard Therapeutics Gene Therapy Product Portfolio Table 103. Orchard Therapeutics Recent Development Table 104. Human Stem Cells Institute Company Information Table 105. Human Stem Cells Institute Business Overview Table 106. Human Stem Cells Institute Gene Therapy Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 107. Human Stem Cells Institute Gene Therapy Product Portfolio Table 108. Human Stem Cells Institute Recent Development Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. Gene Therapy Product Image Figure 2. Global Gene Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 4. Global Gene Therapy Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Viral Gene Therapy Image Figure 8. Non-Viral Gene Therapy Image Figure 9. Global Gene Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Gene Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Gene Therapy Sales Value Share by Type (2021-2032) Figure 12. Neurological Diseases Image Figure 13. Cancer Image Figure 14. Other Image Figure 15. Global Gene Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Gene Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Gene Therapy Sales Value Share by Application (2021-2032) Figure 18. Global Gene Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Gene Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 21. North America Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 27. South America Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Viral Gene Therapy
  • Non-Viral Gene Therapy
Applications
  • Neurological Diseases
  • Cancer
  • Other
Companies covered
  • Biogen
  • Novartis
  • Gilead Sciences
  • Sarepta Therapeutics
  • Alnylam Pharmaceuticals
  • Amgen
  • Spark Therapeutics
  • Akcea Therapeutics
  • bluebird bio
  • Sunway Biotech
  • SIBIONO
  • AnGes
  • Orchard Therapeutics
  • Human Stem Cells Institute

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Gene Therapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Gene Therapy Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Gene Therapy Market Dynamics
  1. 2.1 Gene Therapy Industry Trends
  2. 2.2 Gene Therapy Industry Drivers
  3. 2.3 Gene Therapy Industry Opportunities and Challenges
  4. 2.4 Gene Therapy Industry Restraints
3 Gene Therapy Market by Company
  1. 3.1 Global Gene Therapy Company Revenue Ranking in 2025
  2. 3.2 Global Gene Therapy Revenue by Company (2021-2026)
  3. 3.3 Global Gene Therapy Company Ranking (2024-2026)
  4. 3.4 Global Gene Therapy Company Manufacturing Base and Headquarters
  5. 3.5 Global Gene Therapy Company Product Type and Application
  6. 3.6 Global Gene Therapy Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Gene Therapy Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Gene Therapy Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Gene Therapy Market by Type
  1. 4.1 Gene Therapy Type Introduction
  2. 4.1.1 Viral Gene Therapy
  3. 4.1.2 Non-Viral Gene Therapy
  4. 4.2 Global Gene Therapy Sales Value by Type
  5. 4.2.1 Global Gene Therapy Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Gene Therapy Sales Value by Type (2021-2032)
  7. 4.2.3 Global Gene Therapy Sales Value Share by Type (2021-2032)
5 Gene Therapy Market by Application
  1. 5.1 Gene Therapy Application Introduction
  2. 5.1.1 Neurological Diseases
  3. 5.1.2 Cancer
  4. 5.1.3 Other
  5. 5.2 Global Gene Therapy Sales Value by Application
  6. 5.2.1 Global Gene Therapy Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Gene Therapy Sales Value by Application (2021-2032)
  8. 5.2.3 Global Gene Therapy Sales Value Share by Application (2021-2032)
6 Gene Therapy Regional Value Analysis
  1. 6.1 Global Gene Therapy Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gene Therapy Sales Value by Region (2021-2032)
  3. 6.2.1 Global Gene Therapy Sales Value by Region: 2021-2026
  4. 6.2.2 Global Gene Therapy Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Gene Therapy Sales Value (2021-2032)
  7. 6.3.2 North America Gene Therapy Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Gene Therapy Sales Value (2021-2032)
  10. 6.4.2 Europe Gene Therapy Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Gene Therapy Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Gene Therapy Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Gene Therapy Sales Value (2021-2032)
  16. 6.6.2 South America Gene Therapy Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Gene Therapy Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Gene Therapy Sales Value Share by Country, 2025 VS 2032
7 Gene Therapy Country-level Value Analysis
  1. 7.1 Global Gene Therapy Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Gene Therapy Sales Value by Country (2021-2032)
  3. 7.2.1 Global Gene Therapy Sales Value by Country (2021-2026)
  4. 7.2.2 Global Gene Therapy Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Gene Therapy Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Gene Therapy Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Gene Therapy Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Gene Therapy Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Gene Therapy Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Gene Therapy Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Gene Therapy Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Gene Therapy Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Gene Therapy Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Gene Therapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Gene Therapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Gene Therapy Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Gene Therapy Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Gene Therapy Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Gene Therapy Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Gene Therapy Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Gene Therapy Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Gene Therapy Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Gene Therapy Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Gene Therapy Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Gene Therapy Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Gene Therapy Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Gene Therapy Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Gene Therapy Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Gene Therapy Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Gene Therapy Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Gene Therapy Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Gene Therapy Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Gene Therapy Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Gene Therapy Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Gene Therapy Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Gene Therapy Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Gene Therapy Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Gene Therapy Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Gene Therapy Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Gene Therapy Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Gene Therapy Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Gene Therapy Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Gene Therapy Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Gene Therapy Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Gene Therapy Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Gene Therapy Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Gene Therapy Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Gene Therapy Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Gene Therapy Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Gene Therapy Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Gene Therapy Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Gene Therapy Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Gene Therapy Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Gene Therapy Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Gene Therapy Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Gene Therapy Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Gene Therapy Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Gene Therapy Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Gene Therapy Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Gene Therapy Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Gene Therapy Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Gene Therapy Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Gene Therapy Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Gene Therapy Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Gene Therapy Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Gene Therapy Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Gene Therapy Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Gene Therapy Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Gene Therapy Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Gene Therapy Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Gene Therapy Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Gene Therapy Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Gene Therapy Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Gene Therapy Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Gene Therapy Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Gene Therapy Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Gene Therapy Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Gene Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Biogen
  2. 8.1.1 Biogen Company Information
  3. 8.1.2 Biogen Business Overview
  4. 8.1.3 Biogen Gene Therapy Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Biogen Gene Therapy Product Portfolio
  6. 8.1.5 Biogen Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Gene Therapy Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Gene Therapy Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Gilead Sciences
  14. 8.3.1 Gilead Sciences Company Information
  15. 8.3.2 Gilead Sciences Business Overview
  16. 8.3.3 Gilead Sciences Gene Therapy Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Gilead Sciences Gene Therapy Product Portfolio
  18. 8.3.5 Gilead Sciences Recent Developments
  19. 8.4 Sarepta Therapeutics
  20. 8.4.1 Sarepta Therapeutics Company Information
  21. 8.4.2 Sarepta Therapeutics Business Overview
  22. 8.4.3 Sarepta Therapeutics Gene Therapy Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sarepta Therapeutics Gene Therapy Product Portfolio
  24. 8.4.5 Sarepta Therapeutics Recent Developments
  25. 8.5 Alnylam Pharmaceuticals
  26. 8.5.1 Alnylam Pharmaceuticals Company Information
  27. 8.5.2 Alnylam Pharmaceuticals Business Overview
  28. 8.5.3 Alnylam Pharmaceuticals Gene Therapy Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Alnylam Pharmaceuticals Gene Therapy Product Portfolio
  30. 8.5.5 Alnylam Pharmaceuticals Recent Developments
  31. 8.6 Amgen
  32. 8.6.1 Amgen Company Information
  33. 8.6.2 Amgen Business Overview
  34. 8.6.3 Amgen Gene Therapy Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Amgen Gene Therapy Product Portfolio
  36. 8.6.5 Amgen Recent Developments
  37. 8.7 Spark Therapeutics
  38. 8.7.1 Spark Therapeutics Company Information
  39. 8.7.2 Spark Therapeutics Business Overview
  40. 8.7.3 Spark Therapeutics Gene Therapy Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Spark Therapeutics Gene Therapy Product Portfolio
  42. 8.7.5 Spark Therapeutics Recent Developments
  43. 8.8 Akcea Therapeutics
  44. 8.8.1 Akcea Therapeutics Company Information
  45. 8.8.2 Akcea Therapeutics Business Overview
  46. 8.8.3 Akcea Therapeutics Gene Therapy Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Akcea Therapeutics Gene Therapy Product Portfolio
  48. 8.8.5 Akcea Therapeutics Recent Developments
  49. 8.9 bluebird bio
  50. 8.9.1 bluebird bio Company Information
  51. 8.9.2 bluebird bio Business Overview
  52. 8.9.3 bluebird bio Gene Therapy Revenue and Gross Margin (2021-2026)
  53. 8.9.4 bluebird bio Gene Therapy Product Portfolio
  54. 8.9.5 bluebird bio Recent Developments
  55. 8.10 Sunway Biotech
  56. 8.10.1 Sunway Biotech Company Information
  57. 8.10.2 Sunway Biotech Business Overview
  58. 8.10.3 Sunway Biotech Gene Therapy Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Sunway Biotech Gene Therapy Product Portfolio
  60. 8.10.5 Sunway Biotech Recent Developments
  61. 8.11 SIBIONO
  62. 8.11.1 SIBIONO Company Information
  63. 8.11.2 SIBIONO Business Overview
  64. 8.11.3 SIBIONO Gene Therapy Revenue and Gross Margin (2021-2026)
  65. 8.11.4 SIBIONO Gene Therapy Product Portfolio
  66. 8.11.5 SIBIONO Recent Developments
  67. 8.12 AnGes
  68. 8.12.1 AnGes Company Information
  69. 8.12.2 AnGes Business Overview
  70. 8.12.3 AnGes Gene Therapy Revenue and Gross Margin (2021-2026)
  71. 8.12.4 AnGes Gene Therapy Product Portfolio
  72. 8.12.5 AnGes Recent Developments
  73. 8.13 Orchard Therapeutics
  74. 8.13.1 Orchard Therapeutics Company Information
  75. 8.13.2 Orchard Therapeutics Business Overview
  76. 8.13.3 Orchard Therapeutics Gene Therapy Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Orchard Therapeutics Gene Therapy Product Portfolio
  78. 8.13.5 Orchard Therapeutics Recent Developments
  79. 8.14 Human Stem Cells Institute
  80. 8.14.1 Human Stem Cells Institute Company Information
  81. 8.14.2 Human Stem Cells Institute Business Overview
  82. 8.14.3 Human Stem Cells Institute Gene Therapy Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Human Stem Cells Institute Gene Therapy Product Portfolio
  84. 8.14.5 Human Stem Cells Institute Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst